If AD has an infectious etiology, this may explain the decreased serum A 142 : A 140 ratios evident in AD patients, as the antimicrobial forms of A would be preferentially aggregated in the brain (and therefore not enter the serum) as part of an immune response to the detriment of synaptic regulation and neuronal survival (Soscia et al., 2010
This systematic review aims to summarize and critically evaluate the available in vitro studies investigating the effects of GLP-1-RA on hMSC
Drug Side Effect Mitigation Animal studies suggest BPC-157 may counteract adverse effects of certain pharmaceuticals, particularly NSAIDs, neuroleptics, and prokinetics
Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Pilitsi E, et al
Retatrutide is currently undergoing phase 3 trials and we expect it to be available as a prescription medication in 2029